NCT06830551 The Effect of Cord Blood Serum Eyes Drops Administer in Patients With Severe Keratopathy Related to EGFR-I Treatment
| NCT ID | NCT06830551 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Dry Eye |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2023-09-12 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2023-09-12 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aim to evaluate the efficacy of cord blood eye drops in the healing of the damaged corneal epithelium.
Eligibility Criteria
Inclusion Criteria: * age over 18 years * oncology and advanced cancer patients who have EGFr mutation and who require treatment with antiEGFr drugs * signing of informed consent Exclusion Criteria: * Patients who are unable to store/administer the CSCO independently, or with the help of care-givers.
Contact & Investigator
Luigi Fontana, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06830551 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dry Eye. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06830551 currently recruiting?
Yes, NCT06830551 is actively recruiting participants. Contact the research team at luigi.fontana6@unibo.it for enrollment information.
Where is the NCT06830551 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06830551 clinical trial?
NCT06830551 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Luigi Fontana, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 10 participants.